{"id":53597,"date":"2023-09-20T09:48:06","date_gmt":"2023-09-20T09:48:06","guid":{"rendered":"https:\/\/medsname.com\/votrient\/"},"modified":"2026-04-30T10:25:11","modified_gmt":"2026-04-30T10:25:11","slug":"votrient","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/votrient\/","title":{"rendered":"Votrient"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Votrient?<\/h3>\n<p style=\"margin:0;\"><strong>Votrient<\/strong> is an oral tablet from Novartis containing <strong>pazopanib 400 mg<\/strong> &mdash; a multi-target tyrosine kinase inhibitor (VEGFR-1\/2\/3, PDGFR-&alpha;\/-&beta;, KIT) for <strong>advanced renal cell carcinoma (RCC)<\/strong> \u03ba\u03b1\u03b9 <strong>advanced soft-tissue sarcoma<\/strong> (after prior chemotherapy). Standard dose: <strong>800 mg once daily on an empty stomach<\/strong> (1 hour before or 2 hours after food). <strong>Black-box hepatotoxicity warning<\/strong> &mdash; severe, sometimes fatal, hepatic injury. Mandatory weekly LFTs for first 9 weeks, then monthly. Other key risks: hypertension (~40%), diarrhoea, fatigue, hair colour change (depigmentation), proteinuria, QT prolongation, arterial thrombotic events, GI perforation, wound healing impairment.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 <a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\"><strong>\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>&#9888; Specialist supervision required.<\/strong> Cancer medications must be prescribed by a treating oncologist with a confirmed diagnosis, baseline staging, and a defined treatment plan. Never start, stop, change dose, or use cancer medication outside of an oncology-led care plan. Most cancer drugs require regular blood-test monitoring (FBC, LFT, renal function), are absolutely contraindicated in pregnancy, and have significant drug interactions.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 \u039a\u03c1\u03c5\u03c0\u03c4\u03bf\u03b3\u03c1\u03b1\u03c6\u03b7\u03bc\u03ad\u03bd\u03b7 \u039f\u03bb\u03bf\u03ba\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 \u0391\u03b3\u03bf\u03c1\u03ac\u03c2<\/strong> \u00b7 <strong>\ud83d\udcb3 \u0395\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf\u03c2 \u0395\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae\u03c2<\/strong> \u00b7 <strong>\ud83d\ude9a \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u0391\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/strong> \u00b7 <strong>\u2b50 4.9\/5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">What Is Votrient?<\/h2>\n<p>Votrient is an oral tablet from Novartis containing <strong>pazopanib 400 mg<\/strong>. Pazopanib is a multi-target tyrosine kinase inhibitor active against VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-&alpha;, PDGFR-&beta;, FGFR-1, and KIT. By blocking vascular and growth-factor signalling, it inhibits tumour angiogenesis and growth in vascular tumours.<\/p>\n<h2 class=\"wp-block-heading\">\u03a7\u03c1\u03ae\u03c3\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li><strong>Advanced renal cell carcinoma (RCC)<\/strong> &mdash; first-line and after cytokine therapy<\/li>\n<li><strong>Advanced soft-tissue sarcoma (STS)<\/strong> &mdash; after prior chemotherapy (PALETTE trial)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dosage and How to Take<\/h2>\n<p>\u03a4\u03c5\u03c0\u03b9\u03ba\u03ae \u03b4\u03cc\u03c3\u03b7: <strong>800 mg once daily (2 &times; 400 mg tablets) on an empty stomach<\/strong> &mdash; 1 hour before or 2 hours after any food. Food increases pazopanib absorption ~2-fold, raising toxicity risk.<\/p>\n<ol>\n<li><strong>Empty stomach &mdash; mandatory.<\/strong> Set a routine: dose 1 hour before breakfast, OR 2 hours after dinner before bed.<\/li>\n<li>Swallow tablets whole &mdash; do not crush, dissolve or split (significant absorption change).<\/li>\n<li><strong>Mandatory monitoring:<\/strong> LFTs at baseline, then <strong>weekly for first 9 weeks<\/strong>, then monthly. BP at baseline + every 1&ndash;2 weeks for first 6 weeks, then monthly. ECG (QTc) at baseline + 4&ndash;6 weeks. Urinalysis for proteinuria monthly. TFT (thyroid) every 3 months.<\/li>\n<li>Dose modifications: reduce in 200&ndash;400 mg increments for grade &ge; 3 toxicity, AST\/ALT &gt; 8&times; ULN, severe hypertension, severe proteinuria, or QT prolongation.<\/li>\n<li>Hold pazopanib 7&ndash;14 days before elective surgery; resume 2&ndash;4 weeks after wound healing complete.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n<p><strong>\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2:<\/strong> diarrhoea, fatigue, nausea, decreased appetite, weight loss, hair colour change (depigmentation), hypertension, hand-foot syndrome, taste change, mucositis.<\/p>\n<p><strong>\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03cc:<\/strong><\/p>\n<ul>\n<li><strong>Hepatotoxicity (BLACK BOX)<\/strong> &mdash; severe, sometimes fatal, hepatic injury. Most cases first 4&ndash;9 weeks. Mandatory LFT monitoring.<\/li>\n<li>Hypertension (~40%) &mdash; new-onset or worsening; treat aggressively<\/li>\n<li>QT prolongation and torsades<\/li>\n<li>Arterial thrombotic events (MI, stroke, TIA)<\/li>\n<li>Haemorrhage (epistaxis, GI, intracranial)<\/li>\n<li>GI perforation and fistula<\/li>\n<li>Proteinuria, nephrotic syndrome<\/li>\n<li>Hypothyroidism<\/li>\n<li>Reversible posterior leukoencephalopathy syndrome (PRES)<\/li>\n<li>Impaired wound healing<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u03a0\u03c1\u03bf\u03b5\u03b9\u03b4\u03bf\u03c0\u03bf\u03b9\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<ul>\n<li><strong>\u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7:<\/strong> teratogenic. Reliable contraception throughout treatment + 2 weeks after.<\/li>\n<li><strong>Severe hepatic impairment (Child-Pugh C):<\/strong> contraindicated.<\/li>\n<li><strong>QT prolongation, electrolyte abnormalities:<\/strong> correct hypokalaemia \/ hypomagnesaemia before starting.<\/li>\n<li><strong>Recent arterial thrombotic event (&lt; 6 months):<\/strong> avoid.<\/li>\n<li><strong>Surgery:<\/strong> hold 7&ndash;14 days before; resume 2&ndash;4 weeks after.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">\u03a3\u03c5\u03bd\u03b4\u03c5\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9 \u03bc\u03b5<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">\u0391\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">\u03a4\u03b9 \u03bd\u03b1 \u03ba\u03ac\u03bd\u03b5\u03c4\u03b5<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise pazopanib levels &mdash; toxicity<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce pazopanib dose to 400 mg\/day if unavoidable.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John&#39;s wort)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Lower pazopanib levels &mdash; treatment failure<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">PPIs (omeprazole, esomeprazole, pantoprazole)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce pazopanib absorption substantially &mdash; treatment failure<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Switch to short-acting H2-blocker; separate dosing if H2-blocker required.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">QT-prolonging drugs (citalopram, ondansetron, fluoroquinolones, methadone)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive QT prolongation<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid combinations; ECG monitoring.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u0392\u03b1\u03c1\u03c6\u03b1\u03c1\u03af\u03bd\u03b7<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Bleeding risk; INR variability<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitor INR weekly initially.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u03a7\u03c5\u03bc\u03cc\u03c2 \u03b3\u03ba\u03c1\u03ad\u03b9\u03c0\u03c6\u03c1\u03bf\u03c5\u03c4<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raises pazopanib levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/h2>\n<ul>\n<li>Room temperature, 15&ndash;25&deg;C, original blister.<\/li>\n<li>Out of reach of children, women of childbearing potential, pets.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">\u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2 \u039b\u03cd\u03c3\u03b5\u03b9\u03c2 \u03c3\u03c4\u03bf MedsBase<\/h2>\n<p>Other oncology medications stocked alongside this product:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/imat\/\"><strong>Imat (imatinib 400 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/imatib\/\"><strong>Imatib (imatinib 100 \/ 400 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/veenat\/\"><strong>Veenat (imatinib 100 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/el\/anti-cancer-medication\/\">Browse all anti-cancer medications &rarr;<\/a><\/p>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3 class=\"wp-block-heading\">Why must I take Votrient on an empty stomach?<\/h3>\n<p>Food (especially high-fat) can <strong>double pazopanib absorption<\/strong>, raising blood levels into toxic range and increasing risk of hepatotoxicity, hypertension and QT prolongation. Take 1 hour before any meal OR 2 hours after the last meal. Most patients find it easiest to take pazopanib just before bed (assuming dinner finished &ge; 2 hours earlier) or first thing in the morning.<\/p>\n<h3 class=\"wp-block-heading\">Why is Votrient associated with severe hepatotoxicity?<\/h3>\n<p>Pazopanib carries an FDA <strong>black-box warning for severe, sometimes fatal, hepatic injury<\/strong>. Most cases occur in the first 4&ndash;9 weeks. Mandatory monitoring: LFTs at baseline, then <strong>weekly for the first 9 weeks<\/strong>, then monthly. Stop pazopanib immediately for AST\/ALT &gt; 8&times; ULN, or for any symptoms of hepatic injury (jaundice, dark urine, severe fatigue).<\/p>\n<h3 class=\"wp-block-heading\">Why does my hair colour change on Votrient?<\/h3>\n<p>Pazopanib inhibits tyrosinase (involved in melanin synthesis) as a side effect. Hair depigmentation &mdash; often dramatic, sometimes turning hair white or grey within months &mdash; is reversible on discontinuation. Affects ~40% of patients. Cosmetic only, no clinical significance.<\/p>\n<h3 class=\"wp-block-heading\">How is hypertension managed?<\/h3>\n<p>Pazopanib-induced hypertension is mechanistic (VEGF inhibition reduces nitric oxide synthesis). Affects ~40% of patients, often within first 6 weeks. Treat aggressively: ACE inhibitor or ARB first-line (ramipril, losartan, candesartan), add CCB or diuretic if needed. Avoid stopping pazopanib for hypertension if BP can be controlled &mdash; the hypertension actually correlates with anti-tumour efficacy.<\/p>\n<h3 class=\"wp-block-heading\">Why do I need to stop Votrient before surgery?<\/h3>\n<p>Pazopanib impairs wound healing (VEGF-mediated angiogenesis is central to wound repair) and increases bleeding risk. Hold for <strong>7&ndash;14 days before elective surgery<\/strong>. Resume only after the surgical wound is fully healed, typically <strong>2&ndash;4 weeks post-op<\/strong>. Tell every surgeon and dentist about pazopanib.<\/p>\n<h3 class=\"wp-block-heading\">Can I take a PPI on Votrient?<\/h3>\n<p>PPIs (omeprazole, pantoprazole, esomeprazole) raise gastric pH and substantially reduce pazopanib absorption &mdash; risking treatment failure. Switch to a short-acting H2-blocker (famotidine) and separate dosing by 2+ hours, OR use antacid only when symptomatic, separated by 2+ hours from pazopanib.<\/p>\n<h3 class=\"wp-block-heading\">Can I drink alcohol on Votrient?<\/h3>\n<p>Limit alcohol &mdash; both alcohol and pazopanib are hepatotoxic and the combination amplifies severe liver injury risk. Occasional small amounts may be tolerable but daily or heavy drinking should be avoided.<\/p>\n<h3 class=\"wp-block-heading\">Will Votrient cure my cancer?<\/h3>\n<p>Pazopanib is generally not curative for advanced RCC or sarcoma but produces meaningful disease-control. In RCC, median progression-free survival on pazopanib first-line is approximately 11 months (COMPARZ trial). In sarcoma after chemotherapy, PFS extension is more modest. Treatment continues until progression or unacceptable toxicity. Newer immunotherapy combinations (pembrolizumab + axitinib, nivolumab + cabozantinib) have largely supplanted pazopanib monotherapy for first-line RCC where available.<\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>\u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03c4\u03af\u03b4\u03b1 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ad\u03bd\u03b1 <strong>\u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/strong>. \u039f\u03b9 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b5\u03c2 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03ac, \u03b1\u03c3\u03ae\u03bc\u03b1\u03bd\u03c4\u03b1 \u03c0\u03b1\u03ba\u03ad\u03c4\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5\u03c2 \u03c3\u03c5\u03bd\u03b5\u03c1\u03b3\u03ac\u03c4\u03b5\u03c2 \u03bc\u03b1\u03c2 \u03c3\u03c4\u03b7\u03bd \u03b5\u03ba\u03c0\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 \u03ba\u03b1\u03b9 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd <a href=\"\/el\/medsbase-re-shipment-assurance-policy\/\">\u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>: \u03b5\u03ac\u03bd \u03ad\u03bd\u03b1 \u03b4\u03ad\u03bc\u03b1 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c3\u03c4\u03ad\u03bb\u03bd\u03bf\u03c5\u03bc\u03b5 \u03bc\u03b9\u03b1 \u03b4\u03c9\u03c1\u03b5\u03ac\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Related Anti-Cancer Medications<\/h3>\n<p>Other oncology medications stocked alongside this product:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/imatib\/\">Imatib (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/veenat\/\">Veenat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/imat\/\">Imat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/riborea\/\">Riborea (ribociclib 200 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/keytruda\/\">Keytruda (pembrolizumab 100 mg)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Inhibits cancer cell growth<br \/>\n\u2705 Treats advanced renal cancer<br \/>\n\u2705 Manages soft tissue sarcoma<br \/>\n\u2705 Slows tumor progression<br \/>\n\u2705 Oral administration convenience<\/p>","protected":false},"featured_media":53598,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53597","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/53597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=53597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/53598"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=53597"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=53597"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=53597"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=53597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}